Project Grant NU58DP007789
Award Date
9/30/24
Completion Date
9/29/27
Dollars Obligated
$750K
Funding Federal Agency
National Center for Chronic Disease Prevention and Health Promotion
Awarding Federal Agency
Office of Financial Resources
Federal Grant Program
93.283
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This $827,753 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop more effective gene-mapping methods for rare polygenic disorders like idiopathic pulmonary fibrosis (IPF). The project has three key objectives: (1) developing a network model-based association test informed by pleiotropy to gene expression traits, (2) creating a rare-variant association test accounting for genetic background using...
This $5,715,866 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop a comprehensive understanding of the early stages and progression of pulmonary fibrosis (PF), with the goal of identifying new strategies for early disease detection and prevention. The award supports four interrelated research projects and three core facilities at the University of Michigan and its sub-awardees, Vanderbilt University Medical...
This federal Project Grant award for $595,286.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate a previously unappreciated mechanism of regulating collagen clearance in the lungs. The research seeks to delineate the pathways and upstream/downstream mechanisms governing a cellular homeostatic feedback loop that senses collagen synthesis and regulates its clearance. This work will use mouse...
This federal Project Grant award of $295,924 from the Centers for Disease Control and Prevention (CDC) Investigations and Technical Assistance program (CFDA 93.283) supports the development of a patient-worn negative pressure system to protect healthcare workers from highly transmissible infectious diseases. The award was granted to Inspire RX LLC, a for-profit small disadvantaged business located in Ann Arbor, Michigan. The project aims to develop and evaluate a novel technology that can help...
This $651,019 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is funding research to elucidate the mechanisms behind dysfunctional epithelial repair processes that contribute to the development of pulmonary fibrosis. The research aims to identify factors driving aberrant epithelial cell states, determine the role of HIF signaling in preventing functional alveolar repair, and investigate niche-specific mechanisms regulating...
This federal Project Grant award of $1,929,714.00 from the Centers for Disease Control and Prevention (CFDA 93.283 - Investigations and Technical Assistance program) to Creare LLC, a for-profit engineering research and development company located in Hanover, New Hampshire, will support the refinement of a very low leakage non-invasive ventilation mask for infectious patients. The award period runs from September 1, 2024 to August 31, 2026. The CDC's Investigations and Technical Assistance...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $542,402 to a collaborative research partnership between Henry Ford Health and Michigan State University Health Sciences. The funding supports a 1-year project focused on screening novel compounds that can reverse gene expression profiles associated with idiopathic pulmonary fibrosis (IPF), a devastating lung disease with...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, is focused on investigating the role of cyclin-dependent kinase 9 (CDK9) in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The total funding for this 4-year project is $1,410,668, with a start date of January 1, 2025. The key objectives are to elucidate the molecular mechanisms by which CDK9 regulates IPF pathogenesis and progression,...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $145,642 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Georgia Tech Research Corp to engineer 3D pulmonary microtissue models to study the role of fibroblast senescence in idiopathic pulmonary fibrosis (IPF). The project aims to: 1) develop an in vitro 3D pulmonary microtissue model to assess differences in contractility, stiffness, cell migration, and extracellular matrix (ECM) remodeling...
This $1,546,880 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the regulation of the myofibroblast program in idiopathic pulmonary fibrosis (IPF). The study aims to determine the role of E-box motifs and associated transcription factors, like TWIST1, in driving the myofibroblast phenotype that contributes to lung scarring in IPF. Key research activities include using single-nucleus ATAC-seq to...